Original paper
A human monoclonal antibody blocking SARS-CoV-2 infection
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and...
Figures & Tables
Fig. 1 47D11 neutralizes SARS-CoV and SARS-CoV-2. a Binding of 47D11 to HEK-293T...
Fig. 2 The neutralizing 47D11 mAb binds SARS1-S and SARS2-S RBD without eliminat...
Paper Details
Title
A human monoclonal antibody blocking SARS-CoV-2 infection
Published Date
May 4, 2020
Journal
Volume
11
Issue
1
TrendsPro
You’ll need to upgrade your plan to Pro
Looking to understand a paper’s academic impact over time?
- Scinapse’s Citation Trends graph enables the impact assessment of papers in adjacent fields.
- Assess paper quality within the same journal or volume, irrespective of the year or field, and track the changes in the attention a paper received over time.
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.